Healthcare Technology Go-to-Market Strategy [2026]

Healthcare Tech Go-to-Market Strategy: Why Standard Playbooks Fail in This Industry

I have worked with healthcare technology companies across telehealth, clinical workflow, EHR integrations, patient engagement platforms, and population health analytics. The pattern is always the same. Founders build something genuinely useful for clinicians or health systems, then try to sell it using the same GTM playbook they read in some SaaS blog. Six months later they are burning cash, deals are stalled in committee, and nobody can figure out why a product that users love is not converting into revenue.

The answer is almost always the same: healthcare is structurally different from every other vertical you have sold into, and if your go-to-market strategy does not account for those structural differences, it will fail.

At UpliftGTM, we have helped health tech companies navigate these waters — from early-stage digital health startups to growth-stage platforms selling into large health systems. This playbook captures what actually works, what does not, and where most healthcare technology companies get stuck.

The Four Structural Challenges That Define Healthcare GTM

Before we get into tactics, you need to understand why healthcare GTM is fundamentally different. It is not one thing. It is four things working together to create an environment that punishes generic approaches.

1. Regulatory Complexity Is Not a Checkbox

Every health tech founder knows about HIPAA. Most treat it as a compliance checkbox — get a BAA signed, encrypt your data, check the box. That misses the point entirely.

Regulation in healthcare is not just about data privacy. It touches your marketing claims, your sales process, your implementation timelines, your pricing model, and your ability to integrate with existing systems. FDA clearance for clinical decision support tools. State-level telehealth regulations that change quarterly. CMS reimbursement rules that determine whether your product creates financial value or just clinical value. ONC interoperability requirements that dictate your technical architecture.

I worked with a clinical analytics company that built a brilliant product for predicting patient deterioration. They had strong clinical evidence and users loved it. But their GTM completely ignored the regulatory landscape. They were making clinical outcome claims in their marketing that required FDA clearance they did not have. Their sales team was positioning the product in ways that created liability for health systems. Their implementation timeline did not account for the security review process at academic medical centres.

We spent three months rebuilding their GTM from the regulatory foundation up. Every marketing claim was reviewed against FDA guidance. Sales messaging was rewritten to focus on workflow improvement rather than clinical outcomes. Implementation timelines were adjusted to include the standard security and compliance review periods. It felt like going backwards, but within two quarters their close rate doubled because buyers stopped raising compliance objections halfway through the sales process.

The lesson: regulatory compliance is not a department. It is a GTM strategy. Build it into every function from day one.

2. HIPAA Shapes Everything — Including Your Marketing

HIPAA is the one regulation every health tech company thinks they understand. Most do not. HIPAA does not just govern how you handle patient data. It governs how you can talk about your product, what case studies you can publish, how you run demos, and what data you can use for marketing purposes.

Your case studies cannot include protected health information unless you have explicit authorisation that goes beyond a standard marketing release. Your demo environments need to use synthetic data, not anonymised production data — because "anonymised" has a specific legal definition under HIPAA that most companies do not actually meet. Your marketing team cannot reference specific patient outcomes from implementations without navigating a complex consent process.

This creates a real GTM challenge. In standard B2B SaaS, social proof is your most powerful weapon. In healthcare tech, generating and publishing social proof requires navigating layers of legal review, institutional approval, and compliance clearance. Health systems are notoriously reluctant to serve as public references because their legal teams worry about the liability implications.

The companies that win build their evidence strategy early. They negotiate reference rights into their initial contracts. They invest in clinical studies and publish peer-reviewed research. They build relationships with academic medical centres that have institutional review boards set up to approve this kind of work. It takes longer, but the credibility compounds in ways that a logo wall never could.

3. Sales Cycles Are Long Because Buying Committees Are Large

A typical enterprise SaaS deal might involve four to six stakeholders. A health system deal regularly involves twelve to twenty. And those stakeholders have fundamentally different — and often conflicting — priorities.

The CMIO cares about clinical workflow and evidence. The CIO cares about integration with Epic or Cerner and cybersecurity risk. The CFO cares about ROI and reimbursement impact. The compliance officer cares about HIPAA, state regulations, and liability. The nursing leadership cares about staff burden and change management. The IT security team cares about penetration testing results and SOC 2 reports. The procurement team cares about contract terms and vendor risk assessment scores.

Each of these stakeholders has effective veto power. Miss one and your deal dies — not with a dramatic "no" but with the slow silence of a committee that never reaches consensus.

I have seen health tech deals take eighteen months to close at academic medical centres. I have also seen companies close similar deals in four months. The difference is never the product. It is always the GTM approach. The fast closers identify every stakeholder early, create persona-specific content and collateral for each one, and multi-thread their engagement from the first meeting. The slow closers talk to the clinical champion, build a great relationship, and then get blindsided when IT security kills the deal eight months in.

Your sales process for healthcare needs to map every stakeholder, understand their specific concerns, and arm your champion with the ammunition to address each one. This is not optional. It is the core of health system selling.

4. Multi-Stakeholder Decision-Making Requires Multi-Threaded Selling

This deserves its own section because it is where most health tech companies fail tactically, even when they understand the concept intellectually.

Multi-threaded selling in healthcare means having active relationships with at least three to five stakeholders in every deal. Not "we sent an email to the CIO." Active, engaged relationships where each person understands the value proposition through their specific lens.

Here is what that looks like in practice. Your clinical champion gets clinical evidence, workflow improvement data, and peer references from similar health systems. Your IT contact gets architecture documentation, integration specifications, security certifications, and a technical implementation plan. Your finance contact gets an ROI model built on their specific patient volumes, payer mix, and reimbursement rates. Your compliance contact gets your HIPAA documentation, BAA, and a regulatory compliance matrix. Your nursing leadership gets change management plans, training timelines, and workflow impact assessments.

That is a lot of content. That is a lot of preparation. And it is exactly why health tech companies that try to run a lean, founder-led sales process hit a wall at around ten customers. The complexity demands a system, not heroics.

At UpliftGTM, when we build outbound sales systems for health tech companies, we design the entire process around multi-stakeholder engagement from the start. The sequences, the content, the cadences — all of it assumes that every deal will involve multiple buying personas with different concerns and different timelines.

Targeting Hospitals and Health Systems: Where to Start

Segment Ruthlessly or Waste Everything

"We sell to hospitals" is not an ICP. It is a category. Within that category are community hospitals, regional health systems, academic medical centres, critical access hospitals, specialty hospitals, federally qualified health centres, and integrated delivery networks. Each has different buying processes, budget cycles, technology stacks, and strategic priorities.

Academic medical centres have innovation budgets and research partnerships but glacial procurement processes. Community hospitals have faster decision-making but tighter budgets and less appetite for unproven technology. Large integrated delivery networks can be transformative partners but require enterprise-grade everything — security, scalability, interoperability, and a dedicated account team.

Use a TAM calculator to size your addressable segments, but then go deeper. Look at your existing customers — or if you are pre-revenue, your pilot sites — and identify the characteristics that predict a good fit beyond size and type.

When I work with health tech companies on segmentation, we map five dimensions:

• Technology maturity — Are they on Epic, Cerner, Meditech, or something else? Are they mid-migration? What is their IT team's capacity for new integrations?
• Strategic priorities — What is in their strategic plan? Are they focused on value-based care, operational efficiency, patient experience, or growth? Your product needs to map to a stated priority.
• Financial health — Operating margins in healthcare vary enormously. A system running a 2% margin is not buying new technology unless it directly reduces costs or increases revenue. A system at 8% might have innovation budget available.
• Decision-making structure — Some health systems centralise all technology decisions. Others let individual hospitals or departments make purchases under a certain threshold. The decentralised buyers are faster.
• Regulatory environment — State regulations, Medicaid expansion status, Certificate of Need laws, and local market dynamics all affect buying behaviour and urgency.

A clinical documentation company we advised was initially targeting all hospitals with more than 200 beds. After segmenting properly, they discovered that community hospitals in states with recent Medicaid expansion, running Epic, with operating margins above 4%, closed three times faster and had 50% higher first-year retention. They narrowed their targeting to that segment and their pipeline velocity tripled.

The Health System Buying Cycle You Need to Map

Health systems do not buy on a rolling basis. They budget annually, with most systems finalising their capital and operating budgets between September and December for the following fiscal year. If you are not in the conversation before budget season, you are waiting twelve months.

The typical buying cycle for a new technology platform in a health system looks like this:

1. Problem recognition (ongoing) — A clinical or operational leader identifies a gap. This might be triggered by a patient safety event, a regulatory change, competitive pressure, or a strategic planning process.
2. Internal exploration (2-4 months) — The champion investigates options, talks to peers at conferences, reads industry publications, and builds an internal case for change.
3. Vendor evaluation (3-6 months) — Formal RFP or informal evaluation. Usually three to five vendors. Clinical evaluation, technical assessment, security review, and financial analysis run in parallel.
4. Committee review (2-4 months) — The deal goes through multiple committees: IT governance, clinical informatics, finance, and sometimes the board for larger purchases.
5. Contracting (1-3 months) — Legal negotiation, BAA execution, insurance requirements, SLA agreements, and final procurement approval.
6. Implementation planning (1-2 months) — Technical integration scoping, go-live timeline, change management planning, and resource allocation before the contract is fully executed.

Total elapsed time: nine to twenty months for enterprise deals. Mid-market deals at smaller hospitals or for departmental purchases can close in three to six months.

Your GTM needs to account for this timeline. Your pipeline metrics need to reflect it. Your board needs to understand it. And your cash planning needs to survive it. I have seen health tech companies run out of runway not because their product did not work but because they modelled six-month sales cycles and reality was fourteen months.

Channel Strategy for Healthcare Technology

Outbound: It Works, but Only If You Speak the Language

Cold outbound to health system executives is one of the highest-ROI channels in healthcare tech — when done correctly. The bar for "correctly" is much higher than in standard B2B.

Health system CMIOs, CIOs, and VP-level clinical leaders get bombarded with generic vendor outreach. The emails that get responses are the ones that demonstrate genuine understanding of their specific challenges. Not "our AI platform improves patient outcomes" but "I noticed your system recently received a CMS star rating dip in readmission rates — we helped a similar community health system in your state reduce 30-day readmissions by 18% using a predictive model that integrates directly with Epic."

That level of specificity requires research. It requires understanding the publicly available data — CMS Compare scores, HCAHPS results, state inspection reports, strategic plans posted on their website, conference presentations by their leadership team. It takes more time per prospect, but the response rates justify it.

When we build outbound programmes for health tech clients, we typically see 8-12% response rates on highly targeted, research-backed sequences — compared to 1-2% for generic outbound. The maths is clear: spend more time on fewer, better prospects.

Your outbound team — whether internal or outsourced — needs healthcare domain knowledge. They need to understand the difference between a CMIO and a CMO. They need to know what an ADT feed is. They need to be able to reference MACRA and value-based care without sounding like they just Googled it. This is one area where hiring from the industry, even for SDR roles, pays dividends.

Content and SEO: Building the Authority Engine

Content marketing in healthcare tech serves a different purpose than in standard SaaS. In most SaaS verticals, content drives demand through search traffic and lead generation. In healthcare, content primarily builds clinical credibility and trust. The demand generation follows, but it follows credibility — not the other way around.

The content that works in healthcare tech falls into three categories:

Clinical evidence content — Published research, clinical validation studies, outcome data, and peer-reviewed papers. This is the gold standard. Nothing builds credibility with clinical buyers faster than evidence published in journals they read. If you do not have your own studies, commission them. Partner with academic medical centres. Fund independent evaluations. The investment pays for itself many times over in reduced sales friction.

Regulatory and compliance content — HIPAA guidance, regulatory change analysis, compliance frameworks, and best practice documentation. This content serves two purposes: it attracts search traffic from compliance-focused buyers and it demonstrates that your company understands the regulatory landscape. When a compliance officer sees that your blog regularly analyses ONC rules or CMS policy changes, they are more likely to trust that your product was built with compliance in mind.

Operational and strategic content — Best practices for health system operations, digital transformation playbooks, change management guides, and ROI frameworks. This content targets the operational and financial stakeholders in the buying committee. A CFO who downloads your ROI model and finds it thoughtful and realistic is pre-sold before your sales team ever gets on the phone.

The SEO strategy should focus on intent-rich keywords rather than volume. "EHR integration best practices" might get fewer searches than "healthcare technology trends" but the people searching for it are much closer to a buying decision. Build content clusters around your specific use case and target the long-tail queries that signal evaluation-stage intent.

Events and Conferences: The Relationship Channel

Healthcare is a relationship-driven industry. HIMSS, HLTH, ViVE, CHIME, and the dozens of specialty-specific conferences are not optional — they are where deals start, progress, and sometimes close.

But the ROI from events depends entirely on your approach. Companies that rent a booth, staff it with marketers, and collect badge scans are wasting money. Companies that research the attendee list, schedule fifteen to twenty pre-arranged meetings, host an intimate dinner for target accounts, and have their clinical team present at educational sessions — those companies build pipeline.

Pre-conference outreach is where the value is created. Six to eight weeks before a major conference, identify the target accounts that will be attending. Reach out with a specific reason to meet: a relevant case study, a new feature that addresses their stated priority, an introduction to a peer at another health system who has deployed your solution. The meetings booked before the conference are worth ten times the badge scans collected at the booth.

Post-conference follow-up needs to be immediate and specific. Not "great meeting you at HIMSS" but "you mentioned that readmission rates in your cardiac unit are a board-level priority this year — here is the case study I referenced from a similar programme." Specificity signals that you listened and that you understand their world.

Partner and Channel Strategy: Integration Partners Are Your Secret Weapon

In healthcare technology, your integration partners are often more important than your direct sales efforts. If your product integrates with Epic, Cerner, or another major EHR, that ecosystem is a channel.

Epic's App Orchard (now the Showroom), Oracle Health's marketplace, and similar platforms give you distribution to health systems that are already buying from those vendors. More importantly, a listing on those marketplaces signals that you meet the technical and security standards that health systems require. It is both a distribution channel and a trust signal.

Beyond EHR vendors, look at consulting firms that advise health systems on technology strategy. The Advisory Board, Chartis Group, KLAS Research, and similar organisations influence purchasing decisions. Getting rated by KLAS or featured in their research can accelerate deals significantly because health system buyers trust independent validation.

Technology partners — interoperability platforms like Redox or Health Gorilla, cloud providers with healthcare-specific offerings, cybersecurity vendors that focus on healthcare — are natural referral partners. Their customers need what you build. Build co-marketing programmes, joint case studies, and referral agreements.

Building Clinical Credibility: The Foundation of Everything

Why Clinical Credibility Is Non-Negotiable

In healthcare, credibility is not a nice-to-have. It is a prerequisite for every conversation. Clinical buyers — physicians, nurses, pharmacists, and other clinicians — will not engage with a company that does not demonstrate deep understanding of clinical workflows, patient care, and the realities of practicing medicine.

This is not about having a doctor on your advisory board (although that helps). It is about building an organisation that thinks clinically, communicates clinically, and builds products that reflect genuine understanding of how care is delivered.

The health tech companies that build credibility fastest share a few characteristics:

They hire from the industry. Not just in clinical roles — across the entire organisation. A marketing director who spent five years at a health system writes differently than one who came from a SaaS company. An SDR who used to work in a hospital understands the language, the culture, and the pain points in ways that no training programme can replicate.

They publish evidence, not just content. There is a meaningful difference between a blog post titled "5 Ways to Improve Patient Engagement" and a white paper presenting outcome data from a 12-month deployment across three health systems. The blog post is content. The white paper is evidence. Clinical buyers respond to evidence.

They engage with the clinical community. Contributing to clinical publications. Presenting at medical conferences (not just health tech conferences). Participating in professional organisations like AMIA, HIMSS, or specialty-specific societies. Being present in the spaces where clinicians learn and share.

They speak the language without faking it. Clinicians can spot inauthenticity instantly. If your marketing materials use clinical terminology incorrectly, or your sales team cannot have an informed conversation about clinical workflows, you lose credibility that is almost impossible to recover.

Building Your Clinical Advisory Board

A clinical advisory board is one of the highest-leverage investments a health tech company can make. Done right, it provides clinical credibility, product guidance, research partnerships, and reference customers. Done wrong, it is a list of names on your website that adds no value.

The ideal advisory board for a health tech company includes:

• Practising clinicians who use (or could use) your product daily. They keep you grounded in clinical reality.
• Clinical informatics leaders (CMIOs, CNIOs) who understand both clinical workflows and technology. They bridge the gap between your product team and your end users.
• Health system executives who make purchasing decisions. They give you insight into the buying process and can serve as references.
• Academic researchers who can design and lead clinical studies. They give your evidence strategy credibility.

Compensate them fairly — either with equity, cash retainers, or a combination. Set clear expectations for engagement: quarterly meetings, availability for specific requests (reference calls, content review, product feedback), and an annual in-person strategy session. Treat them as partners, not props.

Evidence Generation as a GTM Strategy

If I could give one piece of advice to every health tech founder, it would be this: start generating clinical evidence from day one. Do not wait until you have a hundred customers. Do not wait until you have funding for a formal study. Start with whatever data you have and build from there.

The evidence hierarchy in healthcare looks like this:

1. Peer-reviewed published studies — The gold standard. Takes time and money but provides unmatched credibility.
2. Conference presentations and abstracts — Faster to produce. Getting a poster or podium presentation at a clinical conference signals that your work meets academic standards.
3. White papers with outcome data — Internally produced but data-driven. Include methodology, sample sizes, and honest discussion of limitations.
4. Case studies with measurable results — Specific implementations with quantified outcomes. The more specific the better — "reduced medication errors by 34% over 12 months" beats "improved patient safety."
5. Testimonials and quotes — The weakest form of evidence but still valuable. Clinical buyers give more weight to testimonials from peers at similar institutions.

Build an evidence roadmap alongside your product roadmap. For each major capability, plan how you will generate evidence to support its value. Budget for it. Staff for it. Treat it as a core business function, not a marketing nice-to-have.

Compliance as a GTM Accelerator, Not a Barrier

Reframing Compliance: From Obstacle to Competitive Advantage

Most health tech companies treat compliance as a cost centre — something they have to do to avoid getting fined. This is backwards. In a market where every buyer is worried about regulatory risk, demonstrating exceptional compliance practices is a competitive differentiator.

When a health system's security team reviews your vendor risk assessment and finds that your documentation is thorough, your certifications are current, and your responses to their questionnaire are detailed and accurate, you have just cleared the biggest hurdle in the sales process. When they review a competitor and find gaps, incomplete documentation, or evasive answers, that competitor is done.

The compliance standards you should have in place before you start scaling your GTM:

• SOC 2 Type II — Non-negotiable. If you do not have this, health systems will not engage.
• HITRUST certification — Increasingly required by larger health systems. Expensive and time-consuming but eliminates an enormous amount of security review friction.
• HIPAA compliance programme — Not just a BAA template. A documented programme with policies, training, incident response procedures, and regular risk assessments.
• State-level compliance — Many states have data privacy and health information laws that go beyond HIPAA. California, New York, and Texas are particularly complex.
• FDA compliance — If your product could be classified as a medical device or clinical decision support tool, you need to understand the regulatory pathway and either pursue clearance or document why it is not required.

Building Compliance Into Your Marketing

Healthcare marketing compliance is a discipline unto itself. The claims you make, the data you reference, and the way you position your product all have regulatory implications.

General principles:

Do not make clinical outcome claims without evidence. "Our platform reduces readmissions" is a claim that requires clinical evidence to support and may trigger FDA scrutiny depending on the product category. "Health systems using our platform have reported reductions in readmission rates" is a claim that requires specific customer permission but is defensible.

Be precise about what your product does and does not do. Overclaiming creates liability for both you and your customers. A health system that buys your product based on marketing claims that turn out to be unsupported will not just churn — they will warn every peer in their network.

Separate marketing claims from clinical claims. You can market workflow efficiency, time savings, and operational improvements with standard evidence. Clinical outcome claims require a higher standard of evidence and may require regulatory review.

Document everything. Every marketing claim should have a documented source. Every case study should have written approval from the featured customer. Every testimonial should have a signed release. When a compliance officer asks "can you substantiate this claim?" the answer should be immediate and specific.

The Compliance Review Workflow

Build a tiered review process for all GTM content:

Tier 1 — Low risk. Industry commentary, educational content, company news. Reviewed by a marketing lead with compliance training. Turnaround: same day.

Tier 2 — Medium risk. Product descriptions, feature announcements, general case studies. Reviewed by compliance and marketing. Turnaround: three to five business days.

Tier 3 — High risk. Clinical claims, outcome data, customer-specific case studies, regulatory guidance content. Reviewed by compliance, legal, and clinical advisory. Turnaround: one to two weeks.

This tiered approach lets your marketing team move fast on the content that matters for SEO and thought leadership while ensuring that high-risk content gets the scrutiny it requires.

The Healthcare Tech GTM Tech Stack

Your technology stack needs to support the unique requirements of healthcare selling. The core components:

CRM with healthcare-specific configuration. Standard Salesforce or HubSpot works, but you need custom objects for health system hierarchies (system > hospital > department > unit), buying committee mapping, compliance document tracking, and integration with healthcare data sources.

Sales engagement platform. Outreach, SalesLoft, or similar — configured with healthcare-specific sequences, compliance-reviewed templates, and integration with your clinical content library.

Content management for clinical evidence. Your clinical studies, white papers, and case studies need to be organised, version-controlled, and easily accessible to your sales team. A clinical resource library that your sales team actually uses is worth more than a hundred blog posts.

Compliance documentation system. Track BAAs, security questionnaires, vendor risk assessments, and certification status. When a prospect's security team sends a 200-question vendor risk assessment, you need to turn it around in days, not weeks.

Analytics and attribution. Healthcare sales cycles are long enough that standard attribution models break down. Build a model that tracks influence across the entire buyer journey — from the first whitepaper download to the conference meeting to the clinical pilot to the signed contract.

Measuring Healthcare GTM Success

Standard SaaS metrics apply in healthcare, but the benchmarks are different and you need additional metrics that reflect the unique dynamics of the market.

Pipeline metrics:

• Pipeline coverage ratio: 4-5x for healthcare (vs. 3x in standard SaaS) because deals fall out more often
• Average sales cycle: track by segment (academic medical centre vs. community hospital vs. ambulatory)
• Multi-threading score: number of engaged stakeholders per deal (target: 5+ for enterprise)

Efficiency metrics:

• Compliance review turnaround time: how fast can you respond to security questionnaires and vendor risk assessments
• Time to first clinical pilot: from first meeting to a live pilot in a clinical environment
• Evidence generation velocity: how many new case studies, papers, or data points you produce per quarter

Revenue metrics:

• Land-and-expand ratio: what percentage of customers expand within 12 months
• Net revenue retention: should be 115%+ if your product delivers clinical and operational value
• Implementation success rate: percentage of implementations that go live on schedule

Track these monthly and review trends quarterly. Healthcare GTM is a long game and monthly fluctuations will be noisy, but quarterly trends tell you whether your system is working.

Frequently Asked Questions

What makes healthcare technology go-to-market strategy different from standard B2B SaaS?

Healthcare tech GTM differs from standard SaaS in four fundamental ways. First, regulatory complexity — HIPAA, FDA, state laws, and CMS requirements touch every aspect of your go-to-market from marketing claims to sales process to implementation. Second, buying committees are dramatically larger, often involving twelve to twenty stakeholders with conflicting priorities and effective veto power. Third, sales cycles are significantly longer, typically nine to twenty months for enterprise health system deals. Fourth, clinical credibility requirements mean you cannot sell on features alone — buyers need evidence, peer validation, and demonstrated understanding of clinical workflows. These structural differences mean that standard SaaS GTM playbooks require fundamental adaptation for healthcare.

How do I handle HIPAA compliance in my healthcare tech marketing?

HIPAA affects marketing in ways most health tech companies do not anticipate. You cannot include protected health information in case studies without explicit authorisation that goes beyond standard marketing releases. Demo environments must use synthetic data rather than anonymised production data. Customer testimonials referencing specific patient outcomes require navigating complex consent processes. Build HIPAA awareness into your marketing team from day one. Create a tiered content review process where clinical claims and customer case studies receive full legal and compliance review. Develop a library of pre-approved language for common marketing scenarios. Treat compliance as a discipline that produces better, more credible marketing rather than a constraint that limits creativity.

How long is a typical sales cycle when selling to hospitals and health systems?

Sales cycles vary significantly by buyer type and deal size. Enterprise deals at large health systems and academic medical centres typically take nine to twenty months from first contact to signed contract. Mid-market deals at community hospitals may close in three to six months. Departmental purchases under certain dollar thresholds can sometimes close in two to four months. The length is driven by committee-based decision-making, security and compliance review, budget cycles, integration assessment, and clinical validation requirements. You cannot eliminate these steps, but you can accelerate them by front-loading trust and compliance documentation, multi-threading across the buying committee from the start, and aligning your sales timeline with the health system's annual budget cycle.

What channels work best for healthcare technology marketing?

The highest-performing channels for health tech are relationship-driven. Industry events and conferences — HIMSS, HLTH, ViVE, CHIME, and specialty-specific conferences — are essential for building relationships and progressing deals. Targeted outbound with deep research and clinical specificity generates strong response rates. Content and SEO build long-term authority, particularly clinical evidence, regulatory analysis, and operational best practice content. Integration partner ecosystems like Epic App Orchard provide distribution and trust signals. Referral networks among health system leaders are powerful because healthcare buyers rely heavily on peer validation. Paid digital tends to underperform for enterprise health tech because the buying process is relationship-driven and committee-based.

How do I build clinical credibility as an early-stage health tech company?

Start by hiring from the industry — clinical team members, advisors, and even GTM staff with healthcare backgrounds. Build a clinical advisory board with practising clinicians, informatics leaders, health system executives, and academic researchers. Begin generating evidence immediately, even if your initial studies are small. Publish in clinical journals, present at medical conferences, and produce white papers with real outcome data. Engage with clinical professional organisations like AMIA and HIMSS. Ensure your marketing materials use clinical terminology correctly and your sales team can hold informed conversations about clinical workflows. Clinical buyers detect inauthenticity instantly, so invest in genuine domain expertise rather than surface-level positioning.

Should health tech companies target large health systems or start with smaller hospitals?

This depends on your product, your stage, and your resources. Smaller community hospitals offer faster sales cycles, simpler buying committees, and quicker implementations — ideal for early-stage companies that need reference customers and evidence. Large health systems offer bigger contracts, higher lifetime value, and more prestigious logos — but the sales cycles are longer, procurement is more complex, and implementation demands are higher. Most successful health tech companies start with mid-size community hospitals to build their evidence base and reference library, then move upmarket once they have the case studies, certifications, and implementation track record that large systems require. Trying to land a major academic medical centre as your first customer is possible but rarely advisable.

What certifications do health tech companies need before selling to health systems?

SOC 2 Type II is the baseline — without it, most health systems will not engage. HITRUST certification is increasingly required by larger health systems and dramatically reduces security review friction. A documented HIPAA compliance programme with policies, training, and incident response procedures is essential. Depending on your product, FDA clearance or documentation of regulatory exemption may be required. State-level compliance with data privacy laws in states like California, New York, and Texas adds additional requirements. Beyond formal certifications, having completed vendor risk assessments from existing health system customers that you can share (with permission) accelerates the review process with new prospects.

What is the biggest mistake health tech companies make in their go-to-market strategy?

The biggest mistake is treating healthcare GTM like standard SaaS GTM. Companies hire SDRs, build outbound sequences, create marketing content, and run paid campaigns without first building the regulatory foundation, clinical credibility, and compliance infrastructure that healthcare buyers require. The result is wasted spend on channels and tactics that cannot produce results because the trust and credibility gap has not been bridged. The second most common mistake is targeting too broadly — trying to sell to all hospitals rather than identifying the specific segment where product-market fit is strongest and sales cycles are shortest. The third is underestimating sales cycle length and running out of cash before deals close. Healthcare GTM requires patience, domain expertise, and a willingness to invest in trust-building before scaling outbound activity.

---

The Healthcare Tech GTM Advantage

Healthcare technology GTM is harder than standard SaaS. The regulations are real. The sales cycles are long. The buying committees are large. The credibility bar is high. The compliance requirements are non-negotiable.

But here is the advantage that most health tech founders miss: because it is hard, the companies that do it well build extraordinary competitive moats. Regulatory expertise, clinical credibility, health system relationships, published evidence, and integration partnerships are not things a competitor can replicate in a quarter. They take years to build. And once built, they compound.

Every health system reference you earn makes the next deal easier. Every clinical study you publish makes the next sales conversation shorter. Every compliance certification you achieve removes friction from every future procurement process. Every conference relationship you build opens doors at other health systems.

The companies that win in healthcare technology are not always the ones with the best product. They are the ones that health system buyers trust — trust to understand their world, trust to handle sensitive data responsibly, trust to implement without disrupting clinical operations, and trust to be a long-term partner rather than a vendor that disappears after the contract is signed.

Build your go-to-market strategy to earn that trust and the technology will sell itself.

If you are building a healthcare technology go-to-market strategy and want to accelerate the process, explore how we work with healthcare companies or read our guide on what makes a go-to-market strategy work for foundational frameworks that apply across all verticals.